Competitors
Recently in July 2012, Amarin Corporation received FDA marketing approval for Vascepa, also referred to as AMR-101. Vascepa will undoubtedly become a major competitor for Lovaza. In clinicial trials, Vascepa was shown to lower triglycerides; while Lovaza also lowers the triglyceride concentration, Vascepa also lowers LDL-C; Lovaza does not. Lovaza was approved to treat people with very high triglyceride levels (>500 mg/dl), Vascepa is also approved for this market; however the company has also demonstrated that the drug can impact levels in people with high triglyceride (> 200 mg/dl and < 500 mg/dl) levels and will file an sNDA for this indication late in 2012.
Read more about this topic: Lovaza